Compare Kohl's Corporation (KSS) vs Novartis AG (NVS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Kohl's Corporation vs Novartis AG — how do they compare? Kohl's Corporation trades at $17.41 (market cap $1.99B), while Novartis AG trades at $154.12 (market cap $290.25B). The key difference: Novartis AG is far larger — about 145.9× Kohl's Corporation's market cap, and Novartis AG pays the higher dividend (3.17%). Which is the better fit depends on your goals.
| KSS | NVS | |
|---|---|---|
Market Cap | $1.99B | $290.25B |
Sector | Consumer Cyclical | Health |
52-Week High | $24.71 | $168.62 |
52-Week Low | $10.42 | $113.50 |
Enterprise Value | $8.10B | $330.27B |
Dividend Yield | 2.85% | 3.17% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Kohl's (KSS) trades at $17.59, up 1.68% on the day, with a bullish technical signal from moving averages. The stock shows deep value metrics with a P/E of 7.27 and P/B of 0.49, while recent earnings beats and a 10% jump in juniors sales (Zacks, 2026-06-30) signal operational improvements. Cash flow turned positive in 2026 projections at $276M, and the company is focusing on proprietary brands and value initiatives to drive traffic.
Outlook: Turnaround efforts under CEO Michael Bender show early progress, but revenue declines persist. Investment case hinges on margin expansion and market share recovery. Risks include intense retail competition and macroeconomic pressure on consumer spending. Analyst consensus is mixed with a $16.75 price target below current levels, suggesting cautious optimism amid execution uncertainty.
Novartis (NVS) trades at $149.85, down 2.54% today, with a bullish technical signal from moving averages but neutral oscillators. The company reported strong 2025 results with $56.67B revenue and $13.98B net income, though recent quarterly EPS results have been mixed. Key developments include FDA approval for Fabhalta and the $1.5B acquisition of Myricx Bio to expand its oncology pipeline.
Outlook remains cautiously optimistic with 68% analyst hold ratings reflecting valuation concerns at 22.03 P/E. Near-term catalysts include Q2 2026 earnings and drug trial readouts, while risks involve pipeline execution and premium valuation pressure. The stock offers stability with robust profitability but faces growth execution tests ahead.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Kohl's Corporation
Kohl's operates 1,165 department stores in 49 states that sell moderately priced private-label and national brand clothing, shoes, accessories, cosmetics, and home furnishings. Most of these stores are in strip centers. Kohl's also operates a large digital sales business. Women's apparel is Kohl's largest category, having generated 27% of its 2021 sales. The retailer, headquartered in Menomonee Falls, Wisconsin, opened its first department store in 1962.
Read more on KSS →About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →
